Show simple item record

dc.contributor.authorHeadrick, Johnen_US
dc.contributor.authorPeart, Jasonen_US
dc.date.accessioned2017-05-03T11:16:42Z
dc.date.available2017-05-03T11:16:42Z
dc.date.issued2005en_US
dc.date.modified2009-09-23T02:38:06Z
dc.identifier.issn15371891en_US
dc.identifier.doi10.1016/j.vph.2005.02.009en_AU
dc.identifier.urihttp://hdl.handle.net/10072/4736
dc.description.abstractThe A3 adenosine receptor (A3AR) is attributed with multiple beneficial actions in ischemic-reperfused myocardium, including modulation of oncotic and apoptotic cell death and enhancement of contractile function. Additionally, the A3AR may attenuate vascular dysfunction and improve long-term outcome from myocardial insult (modulating hypertrophy and angiogenesis). Available evidence indicates that this receptor sub-type is minimally activated by endogenous adenosine during ischemia (A3AR antagonists exerting no effects on ischemic outcome), and is thus amenable to activation with exogenous agonists. Protected phenotypes arise with both pre- and post-ischemic treatment with A3AR agonists, and transient A3AR agonism also triggers early and delayed preconditioned states. The molecular basis for the varied protective actions of the A3AR remains poorly defined, and may well vary between species (e.g. rodent vs. human) and protective responses (e.g. acute vs. delayed protection). Nonetheless, A3ARs may be more promising as therapeutic "anti-ischemic" targets compared with other adenosine receptor subtypes, since A3AR agonists elicit fewer and less significant side-effects. This review addresses current knowledge and controversy regarding the protective actions (and associated signaling) of A3ARs in ischemic-reperfused heart.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_AU
dc.languageEnglishen_US
dc.language.isoen_AU
dc.publisherElsevieren_US
dc.publisher.placeUnited Statesen_US
dc.relation.ispartofstudentpublicationNen_AU
dc.relation.ispartofpagefrom271en_US
dc.relation.ispartofpageto279en_US
dc.relation.ispartofissue5-6en_US
dc.relation.ispartofjournalVascular Pharmacologyen_US
dc.relation.ispartofvolume42en_US
dc.rights.retentionYen_AU
dc.subject.fieldofresearchcode320603en_US
dc.titleA3 adenosine receptor-mediated protection of the ischemic hearten_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.facultyGriffith Health, School of Medical Scienceen_US
gro.rights.copyrightCopyright 2005 Elsevier : Reproduced in accordance with the copyright policy of the publisher : This journal is available online - use hypertext linksen_AU
gro.date.issued2005
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record